title: Contemporary management of tricuspid regurgitation: an updated clinical review.
abstract: Tricuspid regurgitation (TR) is a complex and insidious valvular pathology that represents a complex decision and management algorithm for patients. TR is present in a significant proportion of the population and is especially prevalent in patients with advanced heart failure. Patients with TR have been demonstrated to have a decreased survival even with normal left heart function. TR can be a result of pathology that directly affects the valvular structure (i.e., Ebstein anomaly) or as a result of increased forward pressures (ie, pulmonary hypertension, left heart failure). Conservative management of patients with TR is primarily symptomatic relief. Definitive therapy involves surgical repair of the tricuspid valve. Furthermore, as more patients develop advanced heart failure, the management of TR in patients with left ventricular assist devices has become necessary because of the evidence of increased in-hospital morbidity and a trend toward decreased survival.
authors: Division of Cardiovascular Surgery, Vanderbilt University Medical Center, Vanderbilt Heart and Vascular Institute, Nashville, TN 37232-8802, USA.
authors: Joshua T
authors: JT
authors: Taylor
authors: Geoffrey
authors: G
authors: Chidsey
authors: Thomas G
authors: TG
authors: Disalvo
authors: John G
authors: JG
authors: Byrne
authors: Simon
authors: S
authors: Maltais
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D013504:Cardiovascular Surgical Procedures; D019468:Disease Management; D006353:Heart-Assist Devices; D006801:Humans; D015994:Incidence; D014261:Tricuspid Valve / Q000473:pathology / Q000503:physiopathology / Q000601:surgery; D014262:Tricuspid Valve Insufficiency / Q000453:epidemiology / Q000503:physiopathology* / Q000628:therapy*
chemical_list: D000319:Adrenergic beta-Antagonists